Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright
Rhea-AI Summary
Genelux (NASDAQ: GNLX) has announced its participation in a virtual fireside chat with H.C. Wainwright & Co. on December 16, 2024. The company's President, CEO and Chairman Thomas Zindrick will engage in discussions moderated by Biotech Equity Research Analyst Emily Bodnar, starting at 11:00 a.m. ET.
The session will focus on the clinical program of Olvi-Vec, including its ongoing:
- Phase 3 registration trial in platinum resistant/refractory ovarian cancer (PRROC)
- Phase 1b/2 trial in small-cell lung cancer (SCLC)
- Phase 2 trial in non-small cell lung cancer (NSCLC)
The event will be accessible through registration, with a replay available for approximately 90 days on the company's IR page.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, GNLX declined 7.54%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
WESTLAKE VILLAGE, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board will participate in a virtual fireside chat with H.C. Wainwright & Co. on December 16, 2024.
Biotech Equity Research Analyst, Emily Bodnar, will moderate the HCW@Home session which is scheduled to begin at 11:00 a.m. ET. The discussion will focus on the company’s clinical program of its lead candidate, Olvi-Vec, including its ongoing Phase 3 registration trial in platinum resistant/refractory ovarian cancer (PRROC), Phase 1b/2 trial in small-cell lung cancer (SCLC) and Phase 2 trial in non-small cell lung cancer (NSCLC). To join, please register at https://ct.to/n900Z9K. An archived replay will be available for approximately 90 days following the event on the company’s IR page.
About Genelux Corporation
Genelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company's most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus. Olvi-Vec currently is being evaluated in OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination platinum-doublet + bevacizumab compared with physician's choice of chemotherapy and bevacizumab in patients with platinum-resistant/refractory ovarian cancer. The core of Genelux's discovery and development efforts revolves around its proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. For more information, please visit www.genelux.com and follow us on Twitter @Genelux_Corp and on LinkedIn.
Investor and Media Contacts
Ankit Bhargava, MD
Allele Communications, LLC
genelux@allelecomms.com
Source: Genelux Corporation
FAQ
What clinical trials will be discussed in Genelux's (GNLX) December 16 fireside chat?
When and where can investors access Genelux's (GNLX) H.C. Wainwright fireside chat?
What cancer types is Genelux (GNLX) targeting with Olvi-Vec?
What is the current development stage of Genelux's (GNLX) lead candidate Olvi-Vec?
